Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfoma de Células B Grandes Difuso/diagnóstico por imagen , Neoplasias del Mediastino/diagnóstico por imagen , Adolescente , Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Humanos , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/mortalidad , Masculino , Neoplasias del Mediastino/tratamiento farmacológico , Neoplasias del Mediastino/mortalidad , Persona de Mediana Edad , Tomografía de Emisión de Positrones , Prednisona/administración & dosificación , Pronóstico , Rituximab/administración & dosificación , Tomografía Computarizada por Rayos X , Vincristina/administración & dosificaciónRESUMEN
When the novel agents thalidomide, bortezomib and lenalidomide are administered to patients with myeloma in the context of clinical trials, they are associated with a significant improvement in response, progression-free survival and in some studies, overall survival (OS); however, their effect on the outcome of unselected myeloma patients has not been fully assessed. We compared the outcome of 1376 unselected patients with symptomatic myeloma, who started treatment before or after the introduction of thalidomide. The median OS in patients who started treatment after the introduction of novel agents increased by 12 months (48 vs 36 months, P<0.001). This improvement was more pronounced in patients < or =70 years (from 39 to 74 months, P<0.001), but less evident in patients >70 years (from 26 to 33 months, P=0.27). In patients treated after the introduction of novel agents, the international staging system (ISS) could discriminate three groups with significantly different outcomes (5-year survival for ISS stage I, II and III was 66, 45 and 18%, respectively, P<0.001). ISS was also valid in patients who actually received upfront treatment with novel drugs (4-year survival rate was 85, 61 and 26% for ISS stage I, II and III patients, P=0.001).
Asunto(s)
Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/mortalidad , Estadificación de Neoplasias/estadística & datos numéricos , Talidomida/uso terapéutico , Factores de Edad , Anciano , Análisis de Varianza , Ácidos Borónicos/uso terapéutico , Bortezomib , Evaluación de Medicamentos , Femenino , Grecia , Humanos , Lenalidomida , Masculino , Mieloma Múltiple/diagnóstico , Pirazinas/uso terapéutico , Estudios Retrospectivos , Tasa de Supervivencia , Talidomida/análogos & derivados , Resultado del TratamientoRESUMEN
Renal failure (RF) is a common and severe complication of patients with multiple myeloma (MM). The purpose of our study was to assess the incidence of RF in a contemporary series of newly diagnosed patients with MM, its association with specific clinical and laboratory features, and its impact on patients' outcome. Over the last decade, 756 newly diagnosed symptomatic patients with MM were included in our database. Renal failure, defined as a serum creatinine >or= 2 mg/dl at the time of diagnosis, was seen in 21% of patients. Multiple parameters were associated with RF, but logistic regression analysis showed that RF was independently associated only with International Staging System and Bence Jones proteinuria. The presence of RF was associated with a trend for higher early death rate but with a similar response to primary therapy. The median survival of patients with RF was 19.5 months versus 40.4 months for patients without RF (p < 0.001). Several variables were associated with impaired survival by univariate analysis. When multivariate analysis was performed the independent variables were poor performance status, thrombocytopenia, advanced age, high LDH and elevated serum beta2 microglobulin but not high creatinine. When corrected for stage, renal failure had no impact on survival.
Asunto(s)
Mieloma Múltiple/complicaciones , Insuficiencia Renal/etiología , Anciano , Creatinina/sangre , Femenino , Humanos , Incidencia , Masculino , Pronóstico , Insuficiencia Renal/diagnóstico , Insuficiencia Renal/terapia , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
Trisomy 8 is the most common numerical chromosomal abnormality in myelodysplastic syndromes (MDS). Paroxysmal nocturnal haemoglobinuria (PNH) is an aquired haemolytic anaemia, clonal in nature, due to somatic mutation. PNH may evolve to aplastic anaemia, to MDS or to acute myeloid leukaemia. We present a patient who had trisomy 8 mosaicism at disease presentation who received therapy with all-trans-retinoic acid, responded to therapy, and developed PNH in the course of the disease. Cytogenetics at the time of PNH diagnosis showed a normal karyotype.
Asunto(s)
Cromosomas Humanos Par 8 , Hemoglobinuria Paroxística/complicaciones , Tretinoina/uso terapéutico , Trisomía , Adolescente , Femenino , Humanos , Mosaicismo , Síndromes Mielodisplásicos/complicacionesRESUMEN
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder characterised by an unusual sensitivity of abnormal red cell population(s) to complement lysis, due to a complete or incomplete defect of various surface molecules, including CD55 and CD59. PNH has been associated with various hematological disorders. Using a newly introduced method, the Sephacryl gel test microtyping system, we investigated the presence of CD55 or CD59 defective red cell populations in several hematological disorders. It was also found that a large proportion of such patients possess CD55 deficient populations, while a smaller but still significant proportion possess CD59 deficient populations. Defective red cell populations were detected in normal subjects as well. These findings need further investigation. Nevertheless the Sephacryl Gel Test microtyping system although non specific, seems to be useful in screening for the PNH and/or "PNH-like" red cell defect in several hematological disorders.
Asunto(s)
Eritrocitos/patología , Enfermedades Hematológicas/sangre , Enfermedades Hematológicas/patología , Hemoglobinuria Paroxística/sangre , Inmunofenotipificación/métodos , Antígenos CD55/análisis , Antígenos CD59/análisis , Eritrocitos/inmunología , Hemoglobinuria Paroxística/inmunología , Hemoglobinuria Paroxística/patología , HumanosRESUMEN
We report a man with de novo acute myeloid leukemia (M4 of the FAB classification) bearing two abnormal clones in the bone marrow cells. The clones showed trisomy 11 with loss of the Y chromosome and trisomy 13, respectively.
Asunto(s)
Cromosomas Humanos Par 11 , Cromosomas Humanos Par 13 , Eliminación de Gen , Leucemia Mieloide Aguda/genética , Trisomía , Cromosoma Y , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Médula Ósea/diagnóstico por imagen , Humanos , Cariotipificación , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/tratamiento farmacológico , Masculino , Inducción de Remisión , UltrasonografíaRESUMEN
A case of adult osteopetrosis Type I was diagnosed in a 22-year-old female. She presented for investigation of anaemia with 'myelophthisic' characteristics and extramedullary haemopoiesis which was resistant to haematinics, nandrolone and low-dose corticosteroids. She became progressively transfusion-dependent with gradually worsening thrombocytopenia. She was successfully treated with recombinant erythropoietin. Anaemia as well as thrombocytopenia were corrected. There appeared to be a synergistic action of erythropoietin with steroids.
Asunto(s)
Anemia/terapia , Eritropoyetina/uso terapéutico , Osteopetrosis/terapia , Trombocitopenia/terapia , Adulto , Anemia/etiología , Enfermedades de la Médula Ósea/complicaciones , Enfermedades de la Médula Ósea/terapia , Femenino , Humanos , Proteínas Recombinantes/uso terapéutico , Trombocitopenia/etiologíaRESUMEN
The aim of this study was to define factor(s) influencing fetal erythropoiesis following bone marrow transplantation. Thirty-one transplanted patients (14 males, 17 females) were studied. The underlying diseases were chronic myelogenous leukaemia (CML, 18 patients), acute myeloblastic leukaemia (AML, 7 patients) and acute lymphoblastic leukaemia (ALL, 6 patients). Reticulocyte and peripheral F cell estimation was carried out in donors and patients before transplantation and repeatedly during recovery. For F cell estimation, an indirect immunofluorescence assay was utilized. A significant increase above pre-BMT values in the percentage of F cells was observed in all patients from days 11 to 40 after transplantation. The increase of F cells on days 15, 18, 25, 32, 40 and 50 after transplantation was statistically significant in 14 patients who had shown an increase of F cells following chemotherapy (high responders) compared with the remaining 17 patients who did not respond so significantly. This finding supports the influence of the host bone marrow micro environment. The nature of the mechanisms operating remains to determined.